生存素在胶质瘤患者中的预后作用。
Prognostic role of survivin in patients with glioma.
作者信息
Zhang Sunfu, Zhang Changwei, Song Yanlin, Zhang Jing, Xu Jianguo
机构信息
Department of Neurosurgery, West China Hospital of Sichuan University, The First People's Hospital of Yibin.
West China Medical School of Sichuan University, Sichuan, China.
出版信息
Medicine (Baltimore). 2018 Apr;97(17):e0571. doi: 10.1097/MD.0000000000010571.
BACKGROUND
The aim of this study was to systematically evaluate the prognostic role of survivin in patients with glioma through performing a meta-analysis.
METHODS
PubMed, Web of Science, Cochrane Library, and EMBASE were searched for potentially eligible literature. The study characteristics and relevant data were extracted. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to estimate the prognostic role of survivin in patients with glioma.
RESULTS
Sixteen studies with 1260 patients were included. The pooled HR of higher survivin expression for overall survival was 1.96 (95% CI, 1.57-2.45). The pooled HRs of higher survivin expression for progression- and disease-free survival were 1.62 (95% CI, 0.91-2.90) and 2.41 (95% CI, 0.98-5.90), respectively. Subgroup analyses were also performed.
CONCLUSION
Our results suggested that higher survivin expression was associated with worse overall survival in patients with glioma. The findings may assist future exploration on pathogenesis, diagnosis, anti-survivin therapy, and prognosis in glioma. However, due to the limited study number, more studies are warranted to verify our results.
背景
本研究旨在通过进行一项荟萃分析，系统评估生存素在胶质瘤患者中的预后作用。
方法
检索PubMed、科学网、Cochrane图书馆和EMBASE以获取潜在符合条件的文献。提取研究特征和相关数据。汇总具有95%置信区间（CI）的风险比（HR），以评估生存素在胶质瘤患者中的预后作用。
结果
纳入了16项研究，共1260例患者。生存素高表达与总生存期的汇总HR为1.96（95%CI，1.57 - 2.45）。生存素高表达与进展生存期和无病生存期的汇总HR分别为1.62（95%CI，0.91 - 2.90）和2.41（95%CI，0.98 - 5.90）。还进行了亚组分析。
结论
我们的结果表明，生存素高表达与胶质瘤患者较差的总生存期相关。这些发现可能有助于未来对胶质瘤发病机制、诊断、抗生存素治疗和预后的探索。然而，由于研究数量有限，需要更多研究来验证我们的结果。
Zotero 插件